Breaking News, Collaborations & Alliances

Tiba Biotech, BARDA Partner to Develop Therapeutics Against Influenza

Tiba Biotech's initial focus will be on developing a prototype RNAi-based therapeutic for H1N1 influenza.

Author Image

By: Charlie Sternberg

Associate Editor

Tiba Biotech LLC, a Cambridge-based preclinical biopharmaceutical company, has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), through initiation of an EZ-BAA contract to develop groundbreaking therapeutics against influenza. The $749,999 contract, awarded through a highly competitive review process, supports early-stage thera...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters